| Literature DB >> 26784284 |
M Muñoz-Chimeno1, J E Forero2, J M Echevarría3, J L Muñoz-Bellido4, L Vázquez-López5, L Morago6, M C García-Galera7, A Avellón8.
Abstract
Hepatitis E virus (HEV) genotype 3 produces zoonotic infection associated with the consumption of infected animals. HEV infections can become chronic in immunocompromised (IC) patients. The viral genome has three well defined open reading frames (ORF1, ORF2 and ORF3) within which various domains and functions have been described. This paper (i) describes a new method of complete sequencing of the HEV coding region through overlapping PCR systems, (ii) establishes a consensus sequence and polymorphic positions (PP) for each domain, and (iii) analyzes the complete coding sequence of an IC patient. With regard to the consensus, a high percentage of PP was observed in protease (PP=19%) and the X domain (PP=22%) within ORF1, the N-terminal region of the S domain (PP=22%) in ORF2, and the P1 (PP=35%) and P2 (PP=25%) domains in ORF3. In contrast, the ORF1 Y, ORF2 S, ORF2 M and ORF3 D1 domains were conserved in the reference sequences (0.40, 1, 0.70 and 0% of PP, respectively). The sequence from the IC patient had more mutations in the RpRp (D1235G, Q1242R, S1454T, V1480I, I1502 V, K1511R, G1373 V, E1442D, V1693 M), the terminal ORF2 S- domain (F10L, S26T, G36S, S70P, A105 V, I113 V), the X domain (T938 M, T856 V, S898A) and the helicase (S1014N, S975T, Q1133 K).Entities:
Keywords: Complete genome; HEV; Hepatitis E virus; Immunocompromised
Mesh:
Year: 2016 PMID: 26784284 PMCID: PMC7172825 DOI: 10.1016/j.jviromet.2016.01.004
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014
Oligonucleotides used for amplification of complete HEV coding genome initial reaction (1st R) and nested reaction (2nd R). Tm: annealing temperature. I: inosine.
| 1st R | B1 | B2 | B3 | B4 | B5 | B6 | B7 | B8 | B9 |
|---|---|---|---|---|---|---|---|---|---|
| Name | E3_12S | E3_561S | E3_22S | E3_1527S | E3_2032S | E3_3475S | E3_4759S | E3_5236S | E3_6474S |
| Sequence (5′-3′) | ACGYATGTGGTCGAWGCCATG | ATGGCCCGICAYGGGATGAC | TCGAWGCCATGGAGGCCCA | GGCYTAYGARGGITCIGARGT | TRTGGYTRCAYCCYGAGGG | CTYGGYGAYCCIAAYCAGAT | ATGGARGARTGYGGYATGCC | TGCCTATGYTG CCCGCGC | GCIGCYACRCGI TTYATGAA |
| Name | E3_987A | E3_2091A | E3_1584A | E3_3025A | E3_3781A | E3_5236A | E3_5597A | E3_6648A | E3_7371A |
| Sequence (5′-3′) | AARAGCATRAGCCGRTCCCA | AAIGGRTTIGCIGAYTCCCA | CCRTGRACIGCRTARGTCCC | GGGCGRTGRTTRCGYTCCCA | CTRGCRTCRGCYGTRGCTAT | ACATCRACACARACCTGCGC | GGGTTGGTTGGATGAATATAGGGG | ACWGYYGGCT CACCATTGGC | TTYTAAGRCGC TGAAGYTCAG |
| Size (nt) | 975 | 1530 | 1562 | 1498 | 1749 | 1761 | 838 | 1412 | 897 |
| Tm (°C) | 60 | 60 | 60 | 57 | 57 | 50 | 57 | 57 | 57 |
ORF1 polymorphic positions in reference sequences (PP%) and mutations in IC sequence.
| Protein | Methyltransferase (AA 56–240) | Y domain (AA 216–433) | Polyproline region (variable) | Protease (AA 433–592) | X domain (AA 795–968) | Helicase (AA 970-1202) | RNA polymerase (AA 1217–1703) |
|---|---|---|---|---|---|---|---|
| Summarized function | mRNA ribosome binding, innate immunity | Unknown | Adaptation ( | Protease ( | Unknown | Helicase ( | Replication ( |
| Length (AA) | 184 | 218 | Variable (1) | 160 | 174 | 233 | 487 |
| (PP%) | 5 | 0.40 | 19 | 22 | 6 | 7 | |
| IC sequence mutations | No mutations | No mutations | No insertions. No deletions. | H495C | T938 M, T856 V, S898A | S1014N, S975T, Q1133 K | D1235G, Q1242R, S1454T, V1480I, I1502 V, K1511R, G1373 V, E1442D, V1693 M |
(1) 110 AA in most of the sequences (n = 43); 114 AA (n = 2); 131 AA (n = 3); 172 AA (n = 3);107 AA (n = 7); 108 AA (n = 3); 109 AA (n = 1).
ORF2 and ORF3 polymorphic positions in reference sequences (PP%) and mutations in IC sequence.
| ORF2 protein | ORF3 protein | |||||||
|---|---|---|---|---|---|---|---|---|
| S domain (N-terminal) | S domain (C-terminal) | M domain | P domain | D1 domain | D2 domain | P1 domain | P2 domain | |
| Summarized function | Capsid ( | Connecting S and P domains ( | Neutralizing antibodies binding and cellular receptor ( | Cell survival signal (Zafrullah et al., 1997) | Innate immune response Ratra, (Kar-Roy et al., 2008) | ORF2 interaction (ser71) ( | Virus release ( | |
| Length (AA) | 113 | 203 | 133 | 208 | 122 | |||
| (PP%) | 22 | 1 | 0.70 | 6 | 0 | 16 | 35 | 25 |
| IC sequence mutations | F10L, S26T, G36S, S70P, A105V, I113V | No mutations | T426A | No mutations | No mutations | A36V | No mutations | P110S (included in PXXP motif) |